Welcome to the GARDASIL® Access ProgramUnder the GARDASIL® Access Program, Merck & Co., Inc. (Whitehouse Station, NJ, USA) has pledged to make available at least 3 million doses of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] over the next five years for use in projects in eligible low income countries throughout the world.
The GARDASIL® Access Program Welcomes New Participants
The GARDASIL® Access Program is pleased to announce that, following the May 2009 Advisory Board meeting, six new applicants were recommended for participation in the program. Since inception of the program, organizations and institutions in Bhutan, Bolivia, Cambodia, Ghana, Haiti, India, Lesotho, Moldova, Nepal, Nicaragua, Papua New Guinea, Tanzania and Uzbekistan have been approved to receive more than 390 000 doses of GARDASIL® to gain operational experience in the design and implementation of HPV vaccination projects in their countries.
Click here for more information on the GARDASIL® Access Program
|
Eligible Countries
Organizations and institutions in these countries are invited to submit an application form.
|
